These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

911 related items for PubMed ID: 24099035

  • 1. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
    Juillerat-Jeanneret L.
    J Med Chem; 2014 Mar 27; 57(6):2197-212. PubMed ID: 24099035
    [Abstract] [Full Text] [Related]

  • 2. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA, Gallwitz B.
    Best Pract Res Clin Endocrinol Metab; 2009 Aug 27; 23(4):479-86. PubMed ID: 19748065
    [Abstract] [Full Text] [Related]

  • 3. DPP-4 inhibitors in the treatment of type 2 diabetes.
    Duez H, Cariou B, Staels B.
    Biochem Pharmacol; 2012 Apr 01; 83(7):823-32. PubMed ID: 22172989
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
    Balakumar P, Dhanaraj SA.
    Cell Signal; 2013 Sep 01; 25(9):1799-803. PubMed ID: 23707531
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of dipeptidyl peptidase IV (DPP-IV) by tryptophan containing dipeptides.
    Nongonierma AB, Fitzgerald RJ.
    Food Funct; 2013 Dec 01; 4(12):1843-9. PubMed ID: 24193022
    [Abstract] [Full Text] [Related]

  • 6. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
    Deng J, Peng L, Zhang G, Lan X, Li C, Chen F, Zhou Y, Lin Z, Chen L, Dai R, Xu H, Yang L, Zhang X, Hu W.
    Eur J Med Chem; 2011 Jan 01; 46(1):71-6. PubMed ID: 21106276
    [Abstract] [Full Text] [Related]

  • 7. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S, Roy S, Sethi S, Benjamin B, Sundaram S, Khanna V, Kandalkar SR, Pal C, Kant R, Patra AK, Rayasam G, Mittra S, Saini KS, Paliwal J, Chugh A, Ahmed S, Sattigeri J, Cliff I, Ray A, Bansal VS, Bhatnagar PK, Davis JA.
    Eur J Pharmacol; 2011 Feb 10; 652(1-3):157-63. PubMed ID: 20540938
    [Abstract] [Full Text] [Related]

  • 8. Novel DPP-4 inhibitors against diabetes.
    Liu Y, Hu Y.
    Future Med Chem; 2014 May 10; 6(7):793-808. PubMed ID: 24941873
    [Abstract] [Full Text] [Related]

  • 9. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ.
    J Am Pharm Assoc (2003); 2009 May 10; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [Abstract] [Full Text] [Related]

  • 10. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li N, Wang LJ, Jiang B, Li XQ, Guo CL, Guo SJ, Shi DY.
    Eur J Med Chem; 2018 May 10; 151():145-157. PubMed ID: 29609120
    [Abstract] [Full Text] [Related]

  • 11. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
    Kirby M, Yu DM, O'Connor S, Gorrell MD.
    Clin Sci (Lond); 2009 Sep 28; 118(1):31-41. PubMed ID: 19780719
    [Abstract] [Full Text] [Related]

  • 12. DPP-4 inhibitors: a patent review (2012 - 2014).
    Costante R, Stefanucci A, Carradori S, Novellino E, Mollica A.
    Expert Opin Ther Pat; 2015 Feb 28; 25(2):209-36. PubMed ID: 25482888
    [Abstract] [Full Text] [Related]

  • 13. Susceptibility of milk protein-derived peptides to dipeptidyl peptidase IV (DPP-IV) hydrolysis.
    Nongonierma AB, FitzGerald RJ.
    Food Chem; 2014 Feb 15; 145():845-52. PubMed ID: 24128555
    [Abstract] [Full Text] [Related]

  • 14. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
    Maezaki H, Banno Y, Miyamoto Y, Moritoh Y, Asakawa T, Kataoka O, Takeuchi K, Suzuki N, Ikedo K, Kosaka T, Sasaki M, Tsubotani S, Tani A, Funami M, Yamamoto Y, Tawada M, Aertgeerts K, Yano J, Oi S.
    Bioorg Med Chem; 2011 Aug 01; 19(15):4482-98. PubMed ID: 21741847
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Koska J, Sands M, Burciu C, Reaven P.
    Diab Vasc Dis Res; 2015 May 01; 12(3):154-63. PubMed ID: 25852133
    [Abstract] [Full Text] [Related]

  • 16. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides.
    Sivaraman SA, Sabareesh V.
    Curr Protein Pept Sci; 2024 May 01; 25(4):267-285. PubMed ID: 38173201
    [Abstract] [Full Text] [Related]

  • 17. Recent patents of dipeptidyl peptidase IV inhibitors.
    Mendieta L, Tarrago T, Giralt E.
    Expert Opin Ther Pat; 2011 Nov 01; 21(11):1693-741. PubMed ID: 22017411
    [Abstract] [Full Text] [Related]

  • 18. Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.
    Ahmed HA, May DW, Fagan SC, Segar L.
    Pharmacotherapy; 2015 Mar 01; 35(3):277-97. PubMed ID: 25754657
    [Abstract] [Full Text] [Related]

  • 19. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
    Green JB.
    Postgrad Med; 2012 Jul 01; 124(4):54-61. PubMed ID: 22913894
    [Abstract] [Full Text] [Related]

  • 20. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.
    Meduru H, Wang YT, Tsai JJ, Chen YC.
    Int J Mol Sci; 2016 Jun 13; 17(6):. PubMed ID: 27304951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.